Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02741570
Title Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

oropharynx cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

Carboplatin + Cetuximab + Cisplatin + Fluorouracil

Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | AUT


No variant requirements are available.